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ABSTRACT
Despite metronidazole’s widespread clinical use since the 1960s,
the specific enzymes involved in its biotransformation have not
been previously identified. Hence, in vitro studies were conducted
to identify and characterize the cytochrome P450 enzymes involved
in the formation of the major metabolite, 2-hydroxymetronidazole.
Formation of 2-hydroxymetronidazole in human liver microsomes
was consistent with biphasic, Michaelis-Menten kinetics. Although
several cDNA-expressed P450 enzymes catalyzed 2-hydroxyme-
tronidazole formation at a supratherapeutic concentration of met-
ronidazole (2000 mM), at a “therapeutic concentration” of 100 mM
only CYPs 2A6, 3A4, 3A5, and 3A7 catalyzed metronidazole 2-
hydroxylation at rates substantially greater than control vector, and
CYP2A6 catalyzed 2-hydroxymetronidazole formation at rates 6-
fold higher than the next most active enzyme. Kinetic studies with
these recombinant enzymes revealed that CYP2A6 has aKm = 289mM
which is comparable to the Km for the high-affinity (low-Km)
enzyme in human liver microsomes, whereas the Km values for the
CYP3A enzymes corresponded with the low-affinity (high-Km) com-
ponent. The sample-to-sample variation in 2-hydroxymetronidazole
formation correlated significantly with CYP2A6 activity (r ‡ 0.970,
P < 0.001) at substrate concentrations of 100 and 300 mM. Se-
lective chemical inhibitors of CYP2A6 inhibited metronidazole 2-
hydroxylation in a concentration-dependent manner and inhibitory
antibodies against CYP2A6 virtually eliminated metronidazole 2-
hydroxylation (>99%). Chemical and antibody inhibitors of other
P450 enzymes had little or no effect onmetronidazole 2-hydroxylation.
These results suggest that CYP2A6 is the primary catalyst re-
sponsible for the 2-hydroxylation of metronidazole, a reaction that
may function as a marker of CYP2A6 activity both in vitro and in
vivo.
Introduction
Introduced in 1963 for the treatment of patients with Trichomonas
vaginalis, metronidazole is currently approved by the U.S. Food and
Drug Administration for the treatment of a variety of anaerobic infec-
tions in adults. Although it is not approved for pediatric use, metroni-
dazole is widely used “off-label” to treat serious bacterial and parasitic
infections in children. Metronidazole is believed to exert its bacteri-
cidal activity through the formation of a toxic, redox intermediate
metabolite (nitro reduction) within the bacterium (Edwards, 1980).
Metronidazole undergoes extensive hepatic biotransformation with
subsequent renal elimination (Stambaugh et al., 1968; Jensen and
Gugler, 1983). The major metabolites found in urine result from the
hydroxylation of the 2-methyl group (2-hydroxymetronidazole), oxida-
tion of the 1-ethyl group (1-metronidazole acetic acid), and glucuronide
conjugation (on the 1-ethyl group; Fig. 1). A sulfate conjugate, a further
oxidation product of 2-hydroxymetronidazole and a glucuronide con-
jugate of 2-hydroxymetronidazole have also been identified as minor
metabolites (Stambaugh et al., 1968; Lamp et al., 1999). Although
the parent compound predominates in plasma, along with smaller
concentrations of 2-hydroxymetronidazole (Jensen and Gugler, 1983),
in urine 2-hydroxymetronidazole is the primary metabolite formed
from metronidazole, and accounts for 40–50% of the total met-
ronidazole species present in 24-hour urine samples (Stambaugh
et al., 1968). Both metronidazole and 2-hydroxymetronidazole have
in vitro activity against most anaerobic bacterial strains (O’Keefe
et al., 1982). Of note, the acetic acid metabolite is reported to occur
at detectable levels only in patients with renal dysfunction (Lamp
et al., 1999).
Despite metronidazole’s clinical use for five decades, the specific
enzymes involved in its biotransformation in humans have not been
well characterized. Only one previous study has attempted to char-
acterize the human biotransformation of metronidazole in vitro. This
study, which was conducted in human liver microsomes (HLMs), did
not identify the enzyme(s) responsible for the formation of 2-
hydroxymetronidazole at therapeutic substrate concentrations (Loft et al.,
1991). Knowledge of the enzyme(s) involved in the biotransformation
of metronidazole, and in particular the enzymes responsible for cat-
alyzing the 2-hydroxylation of metronidazole, could be used to predict
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potential drug-drug and drug-xenobiotic interactions in both adults
and children.
Although metronidazole is commonly prescribed to treat anaerobic
pathogens in infants and children with complicated intra-abdominal
infections, only recently have the pharmacokinetics of metronidazole
been characterized in young infants (Suyagh et al., 2011; Cohen-
Wolkowiez et al., 2013). The pharmacokinetic data suggest that a
developmental component exists that influences metronidazole clear-
ance and the exposure-response relationship. Given the predictable
ontogenic profiles for many drug-metabolizing enzymes, identification
of the enzymes responsible for the biotransformation of metronida-
zole is critical for dose optimization in infants and children. There-
fore, the current study was undertaken to characterize the human
cytochrome P450 enzymes responsible for catalyzing the 2-hydroxylation
of metronidazole.
Materials and Methods
Chemicals. Metronidazole, a-naphthoflavone, clopidogrel, diethyldithiocar-
bamic acid, (R)-(–)-deprenyl hydrochloride (selegiline), EDTA, (S)-fluoxetine
hydrochloride, formic acid, furafylline, glucose-6-phospate, glucose-6-phosphate
dehydrogenase, 4-methylpyrazole, 8-methoxypsoralen, mifepristone, b-NADP,
quinidine, sulfaphenazole, ticlopidine, tranylcypromine, and troleandomycin
(TAO) were purchased from Sigma-Aldrich Chemical Co. (St. Louis, MO).
Metronidazole-d4, 2-hydroxymetronidazole, paroxetine hydrochloride, mon-
telukast sodium salt, and (S)-(+)-N-3-benzylnirvanol were purchased from
Toronto Research Chemicals (Toronto, Ontario, Canada). Ketoconazole was
obtained from Research Biochemicals International (Natick, MA). All of the
preceding reagents were of analytical grade. Methanol (Optima MS grade) was
purchased from Thermo Fisher Scientific (Fair Lawn, NJ). All other reagents
were of reagent grade or higher.
Commercial Reagents Biologic. Adult human liver microsomes prepared
from individual donors (1 male, 2 females), a reaction phenotyping kit (Version
7; containing human liver microsomes prepared from 16 individuals: 9 males, 7
females), pooled human liver microsomes (n = 16; mixed genders), inhibitory,
mouse monoclonal antibodies to human CYPs 1A2, 2A6, 2B6, 2C8, 2C9,
2C19, 2D6, 2E1, and 3A4 and control IgG (from rabbits) were obtained from
XenoTech, LLC (Lenexa, KS). Microsomes from baculovirus-infected insect
cells (Supersomes) expressing human P450 enzymes (CYPs 1A1, 1A2, 1B1,
2A6, 2B6, 2C8, 2C9, 2C18, 2C19, 2D6, 2E1, 2J2, 3A4, 3A5, and 3A7) or
control vector were purchased from BD Biosciences (Bedford, MA). All
recombinant enzymes were coexpressed with human NADPH–cytochrome
P450 reductase; some P450s (CYPs 2B6, 2C19, 2E1, 3A4, and 3A7) were also
coexpressed with human cytochrome b5. The manufacturers provided protein
concentrations, P450 contents, and P450 enzyme activities. Vials of micro-
somes were stored at –70°C until use. Microsomes were rapidly thawed in
room temperature water and placed on ice prior to use.
High-Performance Liquid Chromatography/Mass Spectrometry Anal-
ysis of Metronidazole Biotransformation. Metronidazole and 2-hydroxyme-
tronidazole were resolved on a reversed-phase Agilent Technologies (Palo
Alto, CA) Zorbax Eclipse XDB C-18 column (4.6-mm  75-mm, 3.5-mm
particle size) preceded by a Phenomenex C-18 guard column (4-mm  3-mm
i.d., 5-mm particle size) using a Hewlett Packard HP1100 high-performance
liquid chromatography (HPLC) system equipped with a HP1100 degasser,
binary pump, autosampler, column heater, diode array detector, and mass
spectral detector (Hewlett Packard Instruments, Santa Clara, CA). The mobile
phase consisted of 0.1% aqueous formic acid (solvent A) and methanol
containing 0.1% formic acid (solvent B); analytes were eluted isocratically with
an 80:20 mixture of solvent A/solvent B that was delivered at a constant flow of
0.6 ml/minute. The column temperature was maintained at 40°C. Under these
conditions, 2-hydroxymetronidazole and metronidazole eluted at ;2.39 and
2.99 minutes, respectively. The column effluent was monitored by UV de-
tection (313 nm) and by atmospheric pressure electrospray ionization detection
with the mass spectrometer operating in a selective positive ion-monitoring
mode. Ion detection was optimized for detection of 2-hydroxymetronidazole.
The drying gas temperature and flow were maintained at 300°C and 10 l/min,
respectively, and the nebulizer pressure was set at 20 pounds per square inch
[gauge] (psig). The capillary voltage was set at 3 kV. Under these conditions, 2-
hydroxymetronidazole yielded protonated molecular ions (MH+ ions) at a mass
charge ratio (m/z) of 188.2; metronidazole and d4-metronidazole (internal
standard) were monitored as MH+ ions at m/z 172.2 and 176.2, respectively.
Because UV data were used to verify mass spectrometry (MS) data whenever
possible, d4-2-hydroxymetronidazole was not used as an internal standard in
these experiments. Data were collected and integrated with Hewlett Packard
Chemstation software (version B.03.01). 2-Hydroxymetronidazole was quan-
tified by comparison of peak areas with those of analytical standards. The lower
limit of quantification for 2-hydroxymetronidazole was 0.03 mM. The an-
alytical method was linear (r2 . 0.999) over a standard concentration range of
0.03–100 mM. Standard curves run on five separate occasions produced
intraday CVs that ranged from 0.1 to 9.7%, whereas interday CVs ranged from
1.4 to 12.5%.
In Vitro Incubation Conditions. In vitro enzyme assays were performed in
96-well microtiter plates. Standard incubation reactions (100 ml) contained
human liver microsomes (50 mg of microsomal protein) or insect cell mi-
crosomes containing baculovirus-expressed cytochrome P450 enzymes (5 pmol)
coexpressed with P450 reductase, potassium phosphate buffer (50 mM, pH 7.4),
MgCl2 (3 mM), EDTA (1 mM), and metronidazole (16 mM–30 mM) dis-
solved in water at the final concentrations listed. Reactions were initiated
by the addition of an NADPH-generating system, consisting of NADP
(1 mM), glucose-6-phosphate (5 mM), and glucose-6-phosphate dehydroge-
nase (1 IU/ml), incubated at 37 6 0.1°C in a Thermo Forma (Marietta, OH)
Benchtop Orbital Shaker, and terminated after 60 minutes by the addition of
100 ml of ice-cold methanol containing the internal standard, metronidazole-
d4 (2.5 mM final concentration). Protein was precipitated by centrifugation at
10,000 g for 10 minutes. An aliquot (5–20 ml) of the supernatant was analyzed
by HPLC/MS via direct injection.
Preliminary experiments conducted with metronidazole (50, 500, and 5000 mM)
and pooled human liver microsomes (0.1, 0.25, and 0.5 mg protein/ml) suggested
that the rates of formation for 2-hydroxymetronidazole were proportional to
protein concentration (up to 0.5 mg/ml) and incubation time (up to 60 minutes).
Biotransformation of metronidazole did not exceed 10% in incubations in vitro
and incubations conducted without the NADPH-generating system failed to
convert metronidazole to 2-hydroxymetronidazole at detectable levels. Experi-
ments designed to determine kinetic parameters and inhibition experiments with
pooled human liver microsomes were performed in duplicate, and all other
experiments were performed in triplicate.
Chemical Inhibition Experiments. Conversion of metronidazole (100 or
300 mM) to 2-hydroxymetronidazole by human liver microsomes was eval-
uated in the presence or absence (i.e., control) of known P450 isoform-selective
inhibitors, using the incubation conditions described previously. To demon-
strate concentration dependence with competitive inhibitors, a range of in-
hibitor concentrations spanning 30-fold or more was used. The lowest inhibitor
concentrations chosen were determined using the following equation:
Lowest½Inhibitor ¼ ½Drug  KiðinhibitorÞ
KmðdrugÞ
ð1Þ
where [Drug] is the intended final concentration of metronidazole added to the
microsomal incubations, Ki is the inhibition constant of the chemical inhibitor
Fig. 1. Metabolic scheme for the conversion of metronidazole to its major metabolites.
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for a given enzyme, and Km is the Michaelis constant derived for metronidazole
from experiments with pooled human liver microsomes. The Ki values used to
calculate the lowest inhibitor concentrations used in this study were based on
values reported in the literature (Khojasteh et al., 2011). In theory, this
concentration of inhibitor should inhibit ;50% of the selectively inhibited
enzyme’s product formation when [Drug] used in the incubation equals Km. At
the other end of the concentration range, the highest concentration of inhibitor
used in these studies should virtually abolish product formation (by the
inhibited enzyme) under these constraints.
The following competitive chemical inhibitors were examined at the indicated
final concentrations: a-naphthoflavone (CYP1A2, 0.15–5 mM), tranylcypromine
(CYP2A6, 0.2–6 mM), montelukast (CYP2C8, 0.15–5 mM), sulfaphenazole
(CYP2C9, 0.3–10 mM), (S)-(+)-N-3-benzylnirvanol (CYP2C19, 0.3–10 mM),
quinidine (CYP2D6, 0.15–5 mM), 3-methylpyrazole (CYP2E1, 2–60 mM),
and ketoconazole (CYP3A4/5, 0.03–1 mM). Inhibitors were dissolved in
methanol and diluted in the incubation mixtures to a final solvent con-
centration #0.5% (v/v). Control incubations contained an equal volume of
methanol.
Incubations containing the mechanism-based inhibitors (at the indicated final
concentrations) furafylline (CYP1A2, 1 and 10 mM), selegiline (CYP2A6,
30–1000 mM), 8-methoxypsoralen (CYP2A6, 10 mM), diethyldithiocarbamate
(CYP2A6, 50 mM), ticlopidine (CYP2B6, 1 and 3 mM), clopidogrel (CYP2B6,
1 and 3 mM), fluoxetine (CYP2C19, 30 mM), paroxetine (CYP2D6, 1 and 10 mM),
troleandomycin (CYP3A4, 100 mM), or mifepristone (CYP3A4, 2 and 100 mM)
were preincubated with human liver microsomes and NADPH-generating
system for 20 minutes before the reaction was started with substrate. Con-
centrations of mechanism-based inhibitors were based on literature values
(Siu and Tyndale, 2008; Khojasteh et al., 2011) and were dissolved in methanol;
inhibitors were appropriately diluted such that the final solvent concentration in
the incubation mixtures was #0.5% (v/v). Control incubations contained an
equal volume of methanol.
Antibody Inhibition Experiments. Pooled human liver microsomes (50 mg
of microsomal protein) were preincubated at room temperature with ascites
fluid from mice containing inhibitory monoclonal antibodies against human
P450 enzymes or with control IgG, following the manufacturer’s instructions
for maximal inhibition of the indicated enzyme’s activity. Following a 15-
minute preincubation period, potassium phosphate buffer (50 mM, pH 7.4),
MgCl2 (3 mM), EDTA (1 mM), and metronidazole (100 mM) were added to the
incubation mixtures. Reactions were initiated by the addition of an aliquot of
NADPH-generating system and conducted as described previously.
Data Analysis. Correlation coefficients (r) between the rates of 2-
hydroxymetronidazole formation and the activities of cytochrome P450 enzymes
were determined using least-squares regression analysis. Significance was asses-
sed by Pearson’s regression analysis using a two-tailed Student’s t test (Microsoft
Excel 2007) with a significance limit set at a = 0.05. Visual inspection of Eadie-
Hofstee plots (rate versus rate/[S]) derived from kinetic data with human liver
microsomes or with recombinant human P450 enzymes determined whether data
were subsequently fit to a one- or two-enzyme Michaelis-Menten model. Kinetic
data were subsequently analyzed by nonlinear regression without weighting
(GraFit 5; Erithacus Software Ltd, Surrey, UK). For the recombinant enzymes,
CYP3A4 and CYP3A5, kinetic data were best fit to a sigmoidal Vmax equation
equivalent to the Hill equation:
v ¼ ðVmax  SnÞ=ðSn50 þ SnÞ ð2Þ
where S50 is the substrate concentration showing a half-maximal velocity, n is
a measure of cooperativity, and Vmax is the maximal velocity.
Results
Biotransformation of Metronidazole by cDNA-Expressed Hu-
man P450s. As an initial screen to determine which P450 enzymes
were capable of converting metronidazole to 2-hydroxymetronidazole,
a supratherapeutic concentration of metronidazole (2000 mM) was
incubated with control vector or cDNA-expressed CYP1A1, 1A2,
1B1, 2A6, 2B6, 2C8, 2C9, 2C18, 2C19, 2D6, 2E1, 2J2, 3A4, 3A5,
and 3A7. With the exception of CYPs 1A1, 1B1, 2C18, and 2J2, each
of the recombinant enzymes converted metronidazole to 2-hydroxy-
metronidazole (Fig. 2, upper panel). However, CYP2A6, CYP2E1, and
the CYP3A enzymes catalyzed 2-hydroxymetronidazole formation at
rates substantially higher than the other recombinant enzymes tested.
To identify potential candidates for subsequent kinetic analyses,
recombinant enzymes were incubated with a therapeutically relevant
concentration of metronidazole (100 mM). This concentration was
chosen based on a study that examined the pharmacokinetics of
different oral dosages of metronidazole in adults (Amon et al., 1978)
and corroborated by a recent study which examined its pharmacoki-
netics in premature neonates (Cohen-Wolkowiez et al., 2012). Fol-
lowing administration of 250, 1000, and 2000 mg in the adult study
(Amon et al., 1978), peak plasma concentrations of metronidazole
were reported to average 5.1 6 1.7, 19.66 3.8, and 40.6 6 9.3 mg/ml
(equivalent to: 30 6 10, 115 6 22, and 237 6 54 mM), respectively.
At a substrate concentration of 100 mM, only CYPs 2A6, 3A4, 3A5,
and 3A7 catalyzed 2-hydroxymetronidazole formation at rates
substantially greater than the control vector (Fig. 2, lower panel),
with CYP2A6 forming 2-hydroxymetronidazole at rates more than 6-
fold greater than the next most active enzyme (CYP3A5). Although
CYPs 1A1, 2B6, 2C18, and 2C19 also catalyzed formation of 2-
hydroxymetronidazole at this substrate concentration, the rates at
which they contributed to 2-hydroxymetronidazole formation were
extremely low.
Fig. 2. 2-Hydroxymetronidazole formation by human cDNA-expressed cytochrome
P450 enzymes. Metronidazole (2 mM, upper panel; 100 mM, lower panel) was
incubated with heterologously expressed human P450 enzymes as described under
Materials and Methods. Each bar represents the mean6 S.D. of three determinations.
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Determination of Kinetic Parameters. The kinetics of 2-
hydroxymetronidazole formation were investigated in pooled adult
human liver microsomes, in three individual preparations of adult
human liver microsomes [one each with high (H201), moderate (H382),
and minimal (H469) CYP2A6 activity], and in microsomes containing
recombinant CYP2A6, CYP3A4, CYP3A5, and CYP3A7. Visual in-
spection of Eadie-Hofstee plots (Fig. 3) derived from kinetic data with
three of the human liver microsomal preparations (pool, high, and
moderate CYP2A6 activity samples) suggested that the kinetics of
2-hydroxymetronidazole formation might not be consistent with a
simple Michaelis-Menten model. For these samples, the relationship
between the rate of 2-hydroxymetronidazole formation and substrate
concentration was best described by a two-site Michaelis-Menten
equation. Kinetic data from the fourth human liver microsomal sample
(minimal CYP2A6 activity) could be fit to a single-enzyme Michaelis-
Menten model with the kinetic parameters corresponding to the high Km
site for the other three preparations. The affinity constant (Km) for the
low Km site varied only 1.4-fold and there was a 4.3-fold variation in
Vmax (Table 1). The Km values for the high Km site were in the mil-
limolar range and varied 13-fold, whereas the corresponding Vmax
values varied 2.0-fold.
In general, the formation of 2-hydroxymetronidazole by cDNA-
expressed human CYP2A6 and CYP3A7 conformed to a simple,
monophasic Michaelis-Menten model. Although there was a slight
indication of substrate activation of CYP3A7 at the lowest concen-
trations of metronidazole studied (as suggested by the hooked portion
of its Eadie-Hofstee plot, not shown), the majority of the data points
obtained with recombinant CYP3A7 were consistent with Michaelis-
Menten kinetics for a single enzyme. The kinetics of 2-hydroxymet-
ronidazole formation by both CYP3A4 and CYP3A5 displayed
a sigmoidal appearance (indicative of substrate activation) and data
were fit to a derivative of the Hill equation. The apparent Km for
CYP2A6 corresponded to microsomal Km values for the low Km site,
whereas the Km values obtained for CYP3A4, 3A5, and 3A7 were in
the millimolar range and more closely resembled the corresponding
Km values for the high Km site (Table 2).
Chemical Inhibition Experiments. Based on the preceding results,
selective chemical inhibitors of P450 enzymes were incubated with
metronidazole (100 mM) and pooled human liver microsomes to assess
the contribution of CYP2A6 to the formation of 2-hydroxymetronidazole.
The effects of various concentrations of selective, competitive P450
inhibitors on the conversion of metronidazole to 2-hydroxymetronidazole
are illustrated in Fig. 4 (upper panel). The CYP2A6 inhibitor,
tranylcypromine, inhibited the 2-hydroxylation of metronidazole in a
concentration-dependent manner, virtually eliminating product forma-
tion (.96%) at the highest concentration tested (6 mM). All of the other
competitive P450 inhibitors caused little or no inhibition of 2-
hydroxymetronidazole formation.
The effects of various mechanism-based chemical inhibitors on the
formation of 2-hydrozymetronidazole by pooled human liver micro-
somes were examined at concentrations determined to inhibit .80%
of a given P450 isoform’s activity. Diethyldithiocarbamate (DEDC),
8-methoxypsoralen, and selegiline (deprenyl) were the only mechanism-
based inhibitors observed to inhibit the conversion of metronidazole to
2-hydroxymetronidazole (Fig. 4, lower panel). 8-Methoxypsoralen and
selegiline are CYP2A6 inhibitors, whereas DEDC is capable of inhib-
iting both CYP2A6 and CYP2E1. However, at the concentration used
in this study, DEDC is primarily a CYP2A6 inhibitor (Khojasteh et al.,
2011). DEDC inhibited;80% of the formation of 2-hydroxymetronidazole,
whereas the highest concentrations of 8-methoxypsoralen and selegiline
tested inhibited 2-hydroxymetronidazole formation by .95%.
Antibody Inhibition Experiments. To further assess the contribu-
tion of CYP2A6 to metronidazole hydroxylation, the effects of various
inhibitory monoclonal antibodies against human P450 enzymes on the
conversion of metronidazole (100 mM) to 2-hydroxymetronidazole by
pooled human liver microsomes were examined and the results are
illustrated in Fig. 5. Under conditions sufficient to cause maximal
inhibition of each P450 enzyme’s activity, only anti-CYP2A6 markedly
inhibited the formation of 2-hydroxymetronidazole, virtually eliminat-
ing formation of the metabolite (.99%).
Intersubject Variability and Correlation Experiments. A panel
of commercially available human liver microsomes prepared from 16
donors and characterized for P450 isoform activities using marker
substrate reactions were examined for their ability to convert metro-
nidazole to 2-hydroxymetronidazole at two substrate concentrations
(100 and 300 mM). Based on the results of the preceding inhibition
studies, liver microsomes from individuals with high, moderate, and
minimal CYP2A6 activity were also examined for their ability to
catalyze the 2-hydroxylation of metronidazole at these substrate con-
centrations. All of the microsomal samples catalyzed the formation of
2-hydroxymetronidazole from metronidazole, with the exception that
the microsomal sample with minimal CYP2A6 activity failed to
convert 100-mM metronidazole to 2-hydroxymetronidazole. At a sub-
strate concentration of 100 mM, the rate of 2-hydroxymetronidazole
formation varied ;15-fold among samples catalyzing the reaction
[range (rates 6 S.D.): 20.6 6 0.4 to 303 6 20 pmol/mg protein per
minute], whereas at the higher substrate concentration, 2-hydroxymet-
ronidazole formation varied ;100-fold [range (rates 6 S.D.): 4.07 6
0.74 to 4106 20 pmol/mg protein per minute] (Fig. 6; 300 mM results
were similar to those obtained at 100 mM and thus are not shown).
Although the microsomes with minimal CYP2A6 activity were unable
to catalyze the formation of 2-hydroxymetronidazole at detectable
levels at a substrate concentration of 100 mM, these microsomes were
Fig. 3. Effect of substrate concentration on the rate of 2-hydroxymetronidazole
formation by human liver microsomes (Eadie-Hofstee plots). Metronidazole
(16 mM–30 mM) was incubated with pooled human liver microsomes (0.05 mg
microsomal protein) in 100-ml reaction mixtures at 37 6 0.1°C, and terminated with
100 ml of methanol containing metronidazole-d4 (internal standard) after 60
minutes. Following precipitation of microsomal protein, an aliquot (10 ml) of the
supernatant was analyzed by HPLC/MS via direct injection, respectively, as
described under Materials and Methods.
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capable of forming small amounts of 2-hydroxymetronidazole at 300 mM
metronidazole, which markedly increased the variation observed. If the
data for this particular sample are excluded from the analysis, then only
a 12-fold variation is observed among the rates of 2-hydroxymetronidazole
formation in the microsomal samples at a substrate concentration of
300 mM.
The sample-to-sample variation in the rates of 2-hydroxymetroni-
dazole formation correlated significantly with CYP2A6 activity (r $
0.970, P, 0.00001) and with CYP2B6 activity (r $ 0.618, P, 0.01)
at both substrate concentrations examined in the human liver mi-
crosomes from the reaction phenotyping kit (n = 16). Correlations
between activities selective for other P450 isoforms and rates of
2-hydroxymetronidazole formation were not statistically significant
(Table 3). It should be noted, however, that CYP2A6 activity was
significantly correlated with CYP2B6 activity (r $ 0.58, P , 0.02) in
the panel of microsomes used in these studies, which suggests that the
relationship between 2-hydroxymetronidazole formation and CYP2B6
activity may largely be coincidental, particularly since recombinant
CYP2B6 failed to catalyze formation of 2-hydroxymetronidazole at
a substrate concentration of 100 mM. The observed correlation
between CYP2A6 and CYP2B6 activities is not surprising since both
enzymes are known to be transcriptionally coregulated by hepatic
nuclear factor 4a (HNF-4a), estrogen receptor a (ERa), constitutive
androstane receptor (CAR), and the pregnane X receptor (PXR)
(Goodwin et al., 2001; Itoh et al., 2006; Higashi et al., 2007; Wortham
et al., 2007; Lo et al., 2010).
To further characterize the apparent role of CYP2A6-mediated
metronidazole 2-hydroxylation, the panel of human liver microsomes
plus the three individual adult microsomal preparations (with high,
moderate, and low CYP2A6 activity) were incubated with metroni-
dazole (100 or 300 mM) with or without the CYP2A6 inhibitor,
tranylcypromine (6 mM). Tranylcypromine eliminated the formation
of 2-hydroxymetronidazole from 100-mMmetronidazole in all but the four
most active samples, and inhibited the rate of 2-hydroxymetronidazole
formation .95% in these micrsosomal samples, as shown in Fig. 6.
At a substrate concentration of 300 mM, tranylcypromine inhibited
the formation of 2-hydroxymetronidazole by more than 95% in all
but three microsomal samples, and in these samples the inhibitor was
at least 90% effective in reducing the rate of 2-hydroxymetronidazole
formation (results not shown, but the catalytic profile was similar
to that shown in Fig. 6 for the reactions conducted at 100-mM
metronidazole).
Discussion
Data characterizing the enzymes responsible for metronidazole
biotransformation are exceedingly scarce as only one previous in vitro
study (Loft et al., 1991) has addressed this issue. The results of this
study showed that 2-hydroxymetronidazole formation conformed to
biphasic Michaelis-Menten kinetics in human liver microsomes and
that the low Km component had an apparent Km ranging from 140 to
320 mM. Chemical inhibition studies conducted by these authors ruled
out certain P450 enzymes as the low Km catalyst (namely CYPs 1A2,
2C9, 2C19, 2D6, 2E1, and 3A4), but did not identify the enzyme.
Thus, prior to the conduct of the present study, the enzyme(s)
responsible for metronidazole biotransformation were unknown.
The present study was undertaken to fill the “information gap”
regarding the identity and characterization of the P450 enzyme(s)
responsible for metronidazole 2-hydroxylation at substrate concen-
trations approximating those observed in association with therapeutic
doses of the drug. Our results demonstrate that the identity of the low
Km enzyme responsible for catalyzing metronidazole 2-hydroxylation
is CYP2A6. This assertion is well supported by several lines of
evidence: 1) a striking correlation (P , 1  10210) between the rates
of 2-hydroxymetronidazole formation and 7-hydroxycoumarin forma-
tion in a panel of human liver microsomes, 2) virtual elimination of
metronidazole 2-hydroxylation by inhibitory antibodies and selective
chemical inhibitors against CYP2A6 but not against other P450
enzymes, 3) an observed Km for recombinant CYP2A6 (290 mM) that
is similar to the apparent Km for the high affinity (low Km) enzyme in
TABLE 1
Apparent kinetic parameters for the formation of 2-hydroxymetronidazole in human liver microsomes














H201 0.366 6 0.029 0.911 6 0.044 2.48 5.7 6 4.0 1.30 6 0.20 0.22
H382 0.527 6 0.056 0.235 6 0.017 0.45 23.6 6 3.4 1.41 6 0.10 0.06
H469 — — — 75.1 6 10.4 1.44 6 0.12 0.02
Adult Pool 0.383 6 0.040 0.213 6 0.012 0.56 33.1 6 6.5 0.72 6 0.10 0.02
aValue 6 S.E. of parameter fit.
TABLE 2









ml/nmol P450 per minute
CYP2A6 0.289 6 0.061 0.65 6 0.02 — 2.24
CYP3A4 5.38 6 0.42 2.49 6 0.11 1.65 6 0.12 0.46
CYP3A5 4.45 6 0.24 3.46 6 0.10 1.88 6 0.11 0.77
CYP3A7 8.96 6 1.03 1.27 6 0.06 — 0.14
aValue 6 S.E. of parameter fit; bcooperativity coefficient; cintrinsic clearance defined as Vmax/Km or Vmax/S50.
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human liver microsomes (350–500 mM in the present study), and 4)
a high rate of 2-hydroxymetronidazole formation was catalyzed by
recombinant CYP2A6 at a “therapeutic” concentration of 100 mM,
a rate that was ;6-fold greater than the next most active recombinant
enzyme, CYP3A5. Although a number of recombinant P450 en-
zymes displayed the capacity to catalyze 2-hydroxymetronidazole
formation at supratherapeutic concentrations, only CYP2A6 (low
Km) and the three CYP3A enzymes (3A4, 3A5, and 3A7, high-Km,
low-mM range) catalyzed substantial rates of metabolite formation at
metronidazole concentrations approximating those associated with
therapeutic drug administrations. Collectively, these data clearly
demonstrate the predominant catalytic role of CYP2A6 in the
metabolism of metronidazole in humans at “therapeutic” plasma
concentrations.
Large interindividual variability exists in the enzymatic activity
and protein levels of CYP2A6 in human livers and may vary by as
much as 100-fold (Shimada et al., 1994). Part of this variability stems
from genetic factors. CYP2A6 is a highly polymorphic enzyme with
over 37 variant alleles identified to date (http://www.cypalleles.ki.
se/), many of which result in altered activity levels (McDonagh et al.,
2012). In a recent study conducted in 139 mono- and dizygotic twins,
;50% of CYP2A6 activity was attributable to additive genetic in-
fluences after taking into account CYP2A6 genotype (Swan et al.,
2009). Accordingly, projection of CYP2A6 phenotype from CYP2A6
genotype alone may be difficult and in vivo phenotyping studies
will likely be required to obtain an accurate estimate of CYP2A6
activity.
Although CYP2A6 participates in the biotransformation of a number
of compounds, including a variety of pharmaceutical agents and
several promutagens/procarcinogens (Pelkonen et al., 2000), CYP2A6
plays a major role in the metabolism of only a few chemicals and
catalyzes very few reactions specifically. The 7-hydroxylation of
coumarin (Miles et al., 1990; Yamano et al., 1990), the 39-hydroxylation
of cotinine (Nakajima et al., 1996) and the 7-hydroxylation of efavirenz
(Ogburn et al., 2010) are currently the only reactions recognized as being
specifically catalyzed by CYP2A6 at therapeutic concentrations of
substrate. The 2-hydroxylation of midazolam can now be added to this
list.
In vivo probes for CYP2A6 activity in adults have been limited
in the past to coumarin, nicotine, and, to a lesser extent, caffeine
(McDonagh et al., 2012). Neither coumarin nor caffeine is an optimal
probe. Coumarin is not an optimal probe for pharmacokinetic reasons;
it has a short half-life, an extensive and rapid first-pass metabolism
and is present in urine and plasma in low concentrations (Pelkonen,
2002). Caffeine’s utility as a probe for CYP2A6 activity requires
further scrutiny since CYP1A2 has been shown to contribute signi-
ficantly to the formation of the metabolite previously attributable to
CYP2A6 (1,7-dimethyl uric acid) at therapeutic or dietary concentrations
of caffeine (Kimura et al., 2005).
Fig. 4. Effects of various P450 isoform-selective inhibitors on the formation of 2-
hydroxymetronidazole by pooled human liver microsomes. Pooled human liver
microsomes were incubated with metronidazole (100 mM) in the presence or
absence of various selective, chemical inhibitors, with the major P450 inhibited
enclosed in parentheses. Incubations were conducted as described under Materials
and Methods. The upper panel shows the effects of selective, competitive P450
inhibitors, whereas the lower panel shows the effects of mechanism-based inhibitors
on formation of 2-hydroxymetronidazole. Incubations containing mechanism-based
inhibitors were preincubated with human liver microsomes and NADPH-generating
system for 20 minutes prior to initiating the reaction with substrate. Each bar
represents the mean of duplicate determinations.
Fig. 5. Effects of various inhibitory, monoclonal antibodies against human P450
enzymes on the conversion of metronidazole (100 mM) to 2-hydroxymetronidazole
by pooled human liver microsomes. Pooled human liver microsomes (0.05 mg
microsomal protein) were preincubated for 15 minutes at room temperature with
ascites fluid from mice containing inhibitory monoclonal antibodies against human
P450 enzymes or with control IgG followed by incubation with metronidazole
(100 mM), as described under Materials and Methods. Volumes of antibodies used
followed the manufacturer’s recommendations for maximal P450 inhibition. Each
bar represents the mean of duplicate determinations.
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In contrast, nicotine has few issues when determining CYP2A6
phenotype in adults. Nicotine can be administered orally or by transdermal
patch, and single dosing is associated with minimal side effects (Benowitz
et al., 2009). In addition, the metabolic ratio of 39-hydroxycotinine to
cotinine has been validated as an accurate measure of CYP2A6 activity in
vivo (Nakajima et al., 1996), and both of these nicotine metabolites are
readily measured in plasma or noninvasively in saliva and urine (Jacob
et al., 2011).
To our knowledge, neither coumarin nor nicotine has been ad-
ministered as an in vivo probe for CYP2A6 activity in children con-
sequent to ethical considerations regarding nontherapeutic drug use
in pediatrics (de Wildt et al., 2009). However, suitable medications
that are given as a part of routine care or that can be obtained over-the-
counter (e.g., dextromethorphan, caffeine) have been used effectively
as in vivo phenotyping probes in children.
The evidence presented here suggests that metronidazole 2-
hydroxylation certainly can be used to characterize the activity
of CYP2A6 in vitro, particularly at substrate concentrations #100
mM, and potentially in vivo. The majority of metronidazole and 2-
hydroxymetronidazole are excreted via the urine, with 7–12% of
the metronidazole dose eliminated unchanged, and 33–44% excreted as
2-hydroxymetronidazole within a 24-hour period (Nilsson-Ehle et al.,
1981; Houghton et al., 1982). Hence, it is possible that urine sample
collection for phenotyping may be performed noninvasively. The
metabolic ratio of 2-hydroxymetronidazole to metronidazole (either
in urine or plasma) may serve as a useful tool to support CYP2A6
phenotyping in both adults and children given that the drug is com-
monly used to treat a variety of infections in infants and children. Its
potential use as a probe in children is particularly notable because there
are few alternatives to assess CYP2A6 activity in children. In addition,
metronidazole as a single agent or a constituent of a multiagent cocktail,
could potentially be used as a probe to assess CYP2A6 induction or
inhibition in vivo and in vitro. To date, there is only one report of a
phenotyping cocktail containing a suitable phenotyping probe for
CYP2A6 (nicotine) (Petsalo et al., 2008).
The results of the present study also imply that CYP2A6 genotype
could potentially impact the pharmacokinetics and pharmacodynamics
of metronidazole. However, the predictive value of specific allelic
variants could be limited given that both the parent drug and 2-
hydroxymetronidazole are active, have different elimination half-lives,
Fig. 6. Effect of tranylcypromine on the 2-hydroxylation of
metronidazole by a panel of human liver microsomes. Human
liver microsomes (0.05 mg microsomal protein) were incubated
with metronidazole (100 mM) in 100-ml reaction mixtures at 37 6
0.1°C in the presence or absence of tranylcypromine (6 mM),
terminated after 60 minutes with 100 ml of methanol containing
metronidazole-d4, and analyzed by HPLC/MS via direct injection,
as described under Materials and Methods. Bars representing rates
of 2-hydroxymetronidazole formation (inhibited and uninhibited by
tranylcypromine) are the mean 6 S.D. of three determinations.
TABLE 3
Correlation analysis (r) of the relationship between the rates of metronidazole conversion to 2-hydroxymetronidazole
with the sample-to-sample variation in cytochrome P450 activity in human liver microsomes
Values in bold indicate significant correlations between P450 activity and 2-hydroxymetronidazole formation at P , 0.05. Coumarin 7-




100-mM Metronidazole a 300-mM Metronidazole a
r P r P
7-Ethoxyresorufin O-deethylation (CYP1A2) 0.032 0.906 0.068 0.801
Phenacetin O-deethylation (CYP1A2) 0.107 0.692 0.128 0.635
Coumarin 7-hydroxylation (CYP2A6) 0.970 9.19  10211 0.972 5.17  10211
S-Mephenytoin N-hydroxylation (CYP2B6) 0.742 0.001 0.703 0.002
Bupropion hydroxylation (CYP2B6) 0.648 0.006 0.618 0.010
Paclitaxel 6a-hydroxylation (CYP2C8) 0.421 0.102 0.395 0.127
Diclofenac 49-hydroxylation (CYP2C9) 0.181 0.502 0.165 0.540
S-Mephenytoin 49-hydroxylation (CYP2C19) 0.419 0.010 0.375 0.149
Dextromethorphan O-demethylation (CYP2D6) 20.072 0.791 20.112 0.679
Chlorzoxazone 6-hydroxylation (CYP2E1) 20.106 0.695 20.102 0.706
Testosterone 6b-hydroxylation (CYP3A4/5) 0.282 0.288 0.221 0.410
Midazolam 19-hydroxylation (CYP3A4/5) 0.298 0.260 0.245 0.359
Lauric acid 12-hydroxylation (CYP4A9/11) 20.218 0.415 20.214 0.424
r, Correlation coefficient.
aConcentration of metronidazole present in microsomal incubations.
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and variable sensitivity profiles with different pathogens (O’Keefe et al.,
1982; Lamp et al., 1999). Clearly, further studies will be required to
determine the impact of CYP2A6 genotype on metronidazole dispo-
sition and effect.
Although progress has been made in recent years to characterize the
ontogenic profiles of many drug metabolizing enzymes, including the
cytochromes P450, (Kearns et al., 2003; Hines, 2007), little is known
regarding the developmental acquisition of CYP2A6 activity. CYP2A6
has been detected by Western blot in both fetal liver and olfactory
mucosa; however, protein levels were not quantified (Gu et al., 2000).
In another report, where CYP2A6 content was measured immuno-
chemically in liver samples from 4 neonates, 6 infants, and 10 pediatric
donors, it was found that CYP2A6 was expressed in all livers, but that
there was no difference in the protein expression pattern between the
pediatric-aged donors and the combined group of neonates and infants
(Tateishi et al., 1997).
In that 2-hydroxymetronidazole is the predominant metabolite
formed from metronidazole, it follows that CYP2A6 activity could
serve as a major determinant of metronidazole plasma clearance.
Consequently, characterizing the pharmacokinetics of the drug in
neonates, infants, and children could provide a phenotypic depic-
tion of the impact of ontogeny on CYP2A6 activity. This assertion
is supported by limited pharmacokinetic data in the literature.
An early study that compared metronidazole pharmacokinetics be-
tween children and adults failed to yield appreciable age-related
differences (Amon et al., 1983). In contrast, pharmacokinetic param-
eters in young infants appear to be markedly different from those in
adults. For example, the apparent elimination half-life of metronida-
zole is increased 2- to 3-fold in young infants and decreases with
increasing postnatal age (Jager-Roman et al., 1982; Hall et al.,
1983; Upadhyaya et al., 1988). Another previous report demon-
strated that in seven infants less than 8 weeks of age, the mean
metronidazole elimination half-life was 18.4 hours compared with
a corresponding value of 7 hours in four infants over 8 weeks of
age (Rubenson and Rosetzsky, 1986). Finally two recent studies in
preterm infants demonstrated significant increases in metronida-
zole clearance over the first weeks and months of life (Suyagh
et al., 2011; Cohen-Wolkowiez et al., 2013). Despite these
apparent developmental differences in metronidazole elimination,
it is not yet known at what age the clearance or elimination half-
life of metronidazole becomes comparable between children and
adults.
In summary, the in vitro studies presented here suggest that CYP2A6
is the predominant catalyst of metronidazole 2-hydroxylation in
humans at therapeutic concentrations. Furthermore, at a substrate
concentration of 100 mM, this reaction appears to function as a
biomarker of CYP2A6 activity, with $96% of 2-hydroxymetroni-
dazole formation attributed to CYP2A6. The current in vitro studies
coupled with recent pharmacokinetic data in preterm and term neo-
nates (Suyagh et al., 2011; Cohen-Wolkowiez et al., 2013) suggest
that metronidazole may be a sensitive probe for CYP2A6 activity
that may be sufficient to characterize the impact of ontogeny on the
activity of this enzyme.
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